Adverse drug reactions associated with antiretroviral therapy during pregnancy

Expert Opinion on Drug Safety

Volumn 13, Issue 12, 2014, Pages 1623-1652

  Santini Oliveira, Marilia ^a   Grinsztejn, Beatriz ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Adverse drug reactions; Antiretroviral; HIV; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

ADVERSE DRUG REACTION; DISEASE COURSE; DRUG SAFETY; DRUG SCREENING; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NONHUMAN; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VERTICAL TRANSMISSION; ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; PREGNANCY COMPLICATIONS, INFECTIOUS;

ANIMALS; ANTI-RETROVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84912032883     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.975204     Document Type: Review

References (166)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. World Health Organization; United States: 2013
2. Bryson YJ. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996;10(Suppl 3):S33-42
3. Mofenson LM. Mother-child HIV-1 transmission. Obstet Gynecol Clin North Am 1997;24:75-84
4. Nielsen K, Joaõ Filho EC, Grinsztejn B, et al. Effect of Antiretroviral treatment on the reduction of perinatal HIV transmission in Brazil [abstract 23607]. XII World Aids Conference, Geneva, Switzerland; 1998
5. Rubini N, Arabe J, Leal DWC, et al. Main difficulties in the reduction of HIV vertical transmission in Rio de Janeiro, Brazil [abstract 23311]. From Program and Abstracts of the 12th World Aids Conference, Geneva, Switzerland; June-July 1998
6. Mussi-Pinhata MM, Kato CM, Duarte G, et al. Factors associated with vertical HIV transmission during two different time periods: the impact of zidovudine use on clinical practice at a Brazilian reference centre. Int J STD AIDS 2003;14:818-25
7. Mofenson LM. Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clin North Am 1997;24:759-84
8. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992;340:582-8
9. Datta P, Embree JE, Kreiss JK, et al. Mother-to~child transmission of Human Immunodeficiency Virus type 1: report from the Nairobi Study. J Infect Dis 1994;170:1134-40
10. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial. JAMA 2000;283:1167-74
11. Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 2001;15:1157-65
12. Newell ML. Vertical transmission of HIV-1 infection. Trans R Soc Trop Med Hyg 2000;94:1-2
13. Wabwire-Mangen F, Gray RH, Mmiro FA, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999;22:379-85
14. Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann N Y Acad Sci 2000;918:84-98
15. Van Dyke RB, Korber BT, Popek E, Koopmans PP. The Ariel Project: A prospective cohort study of maternalchild transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999;179:319-28
16. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60
17. The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial. Lancet 1999;353:1035-9
18. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A metaanalysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87
19. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9
20. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1. French Perinatal Cohort Studies. SEROGEST Cohort Group. J Infect Dis 1997;175:172-5
21. Garcia PM, Kalish LA, Pitt J, et al. RNA and transmission: maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study (WITS). N Engl J Med 1999;341:394-402
22. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. AIDS 1999;3:1377-85
23. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999;353:773-80
24. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads
25. Read JS, Newell ML. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005;4:CD005479
26. Leroy V, Newell ML, Dabis F, et al. International multicenter pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998;352:597-600
27. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of HIV-1. J Infect Dis 2003;187:725-35
28. Phadke MA, Bulakh PM, Kshirsagar NA. Nevirapine to prevent HIV transmission via breastfeeding. Lancet 2008;372:287-91
29. Coll Hernandez M, Boucher CA, Fortuny C, et al. Vertical HIV-1 transmission correlated with a high maternal viral load at delivery. JAIDS 1997;14:26-30
30. Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr 2010;54:27-34
31. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of Human Immunodeficiency Virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80
32. CDC (Centers for Disease Control and Prevention). Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission-Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep 1998;47:151-4
33. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV-1 in breastfed children in Cote d' Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-92
34. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV-1 in Kampala, Uganda: HIV-1NET 012 randomised trial. Lancet 1999;354:795-802
35. Shaffer N, Roongpitsuthipong A, Siriwaisn W, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission. Thailand. J Infect Dis 1999;179:590-9
36. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV-1 Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343:982-91
37. Petra Study Team. Efficacy of three short course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): A randomised double-blind, placebo-controlled trial. Lancet 2002;359:1178-86
38. Gandhi M, Mwesigwa J, Aweeka F, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013;63(5):578-84
39. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005;19:1289-97
40. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: A randomized trial: the Mashi Study. JAMA 2006;296:794-805
41. Fowler MG, Lampe MA, Jamieson DJ, et al. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 2007;197:S3-9
42. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14
43. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012;366:2368-79
44. Joaõ EC, Cruz ML, Menezes JA, et al. Vertical transmission of HIV in Rio de Janeiro. Brazil. AIDS 2003;17:1853-5
45. Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery and viral load in 2895 US women (PACTG 367) [Oral abstract]. 11th CROI. San Francisco-CA; EUA. 2004
46. Kreitchmann R, Fuchs SC, Suffert T, Preussler G. Perinatal HIV-1 transmission among low income women participants in the HIV/AIDS Control Program in Southern Brazil: A cohort study. BJOG 2004;111:579-84
47. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010(3):CD008440
48. Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. Aids Rev 2011;13:198-213
49. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in botswana. N Engl J Med 2010;362:2282-94
50. The Kesho Bora Study Group. Maternal HIV-1 Disease Progression 18-24 Months Post-Delivery According to Antiretroviral Prophylaxis Regimen (Triple-Antiretroviral Prophylaxis during Pregnancy and Breastfeeding Versus Zidovudine/Single-Dose Nevirapine Prophylaxis): the Kesho Bora Randomized Controlled Trial. Clin Infect Dis 2012;55:449-60
51. Azria E, Moutafoff C, Schmitz T, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther 2009;14(3):423-32
52. Peixoto MF, Pilotto JH, Stoszek SK, et al. Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. Braz J Infect Dis 2011;15:253-61
53. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21:2409-15
54. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIVinfected pregnant women. HIV Med 2011;12:570-9
55. Nav-er L, Albert J, Belfrage E, et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: swedish recommendations 2010. Scand J Infect Dis 2011;43:411-23
56. Santini-Oliveira M, Estrela Rde C, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard-And increased-dosage lopinavirritonavir coformulation tablets in HIVpositive pregnant women. Antimicrob Agents Chemother 2014;58:2884-93
57. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505
58. World Health Organization 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available from: www. who.int/hiv/pub/guidelines/arv2013/en/[Accessed on 16 July 2014]
59. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Sex differences in zidovudine and lamivudine triphosphate concentrations in HIV-infected patients. AIDS 2003;17(15):2159-68
60. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetic and therapeutic drug monitoring of antiretrovirals in pregnant women. BJCP 2008;66:179-95
61. Knoppert D. Safety and efficacy of drugs in pregnancy. J Popul Ther Clin Pharmacol 2011;18(3):e506-12
62. Colbers A, Greupink R, Burger D. Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis 2013;26:575-88
63. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann NY Acad Sci 2000;918:287-97
64. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis 2002;21:835-8
65. Santini-Oliveira M, Friedman RK, Veloso VG, et al. Incidence of antiretroviral adverse drug reactions in pregnant women in two referral centers for HIV prevention of mother-to-childtransmission care and research in Rio de Janeiro. Brazil. Braz J Infect Dis 2014;18:372-8
66. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-9
67. CDC (Centers for Disease Control and Prevention). Recommendations for use of antiretroviral drugs in pregnant HIV infected women for maternal health and interventions to reduce perinatal transmission in the United States. 2004
68. Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine HIV Med 2009;10:397-406
69. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7:255-60
70. Kondo W, Carraro EA, Prandel E, et al. Nevirapine-induced side effects in pregnant women: experience of Brazilian university hospital. Braz J Infect Dis 2007;11:544-8
71. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-Associated toxicity in HIVinfected Thai men and women, including pregnant women. HIV Med 2007;8:357-66
72. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-Associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007;44:371-6
73. Aaron E, Kempf MC, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One 2010;5:e12617
74. Bera E, Mia R. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: A systematic review and meta-Analysis. S Afr Med J 2012;102:855-9
75. Ford N, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine use in pregnancy: A systematic review and meta-Analysis. AIDS 2013;27:1135-43
76. Eshelman SH, Mracna M, Guay LA, et al. Selection of fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7
77. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007;51(3):896-901
78. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:35-47
79. Giaquinto C, Rampon O, De Rossi A. Antiretroviral therapy for prevention of mother-to-child HIV transmission: focus on single-dose nevirapine. Clin Drug Investig 2006;26:611-27
80. Ellis GM, Huang S, Hitti J, Frenkel LM; P1022 Study Team. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr 2011;58:241-7
81. Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11-16
82. Tubiana R, Mandelbrot L, Delmas S, et al. LPV/r Monotherapy during pregnancy for PMTCT of HIV-1: The PRIMEVA/ANRS 135 Randomized Trial, pregnancy outcomes. Paper # 125LB 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011
83. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931-9
84. Bonafe SM, Costa DA, Vaz MJ, et al. A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy. AIDS Patient Care STDS 2013;27:589-95
85. Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010;24:2193-200
86. Else LJ, Douglas M, Dickinson L, et al. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012;56(2):816-24
87. Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med 2011;12:166-73
88. Best BM, Stek AM, Mirochnik M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010;54(4):381-8
89. Patterson KB, Diamond JB, Prince HA, et al. Pharmacokinetics of the lopinavir/ritonavir tablet in HIV-infected pregnant women: A longitudinal investigation of protein bound and unbound drug exposure with empiric dosage adjustment. 18th CROI, Boston-MA, EUA; 2011. Paper #645
90. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360:1152-4
91. Mawson AR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. Lancet 2003;361:347-8
92. Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against pre-eclampsiaeclampsia Obstet Gynecol 2004;104(2):238-42
93. Mattar R, Amed AM, Lindsey PC, et al. Pre-eclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol 2004;117:240-1
94. Haeri S, Shauer M, Dale M, et al. Obstetric and newborn infant outcomes in human immunodeficiency virusinfected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009;201:e311-15
95. Boyajian T, Shah PS, Murphy KE. Risk of pre-eclampsia in HIV-positive pregnant women receiving HAART: A matched cohort study. J Obstet Gynaecol Can 2012;34:136-41
96. Machado ES, Krauss MR, Megazzini K, et al. Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries. J Infect 2014;68:572-80
97. Chougrani I, Luton D, Matheron S, et al. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) 2013;5:253-62
98. Watts DH, Balasubramanian R, Maupin RT Jr, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004;190:506-16
99. El Beitune P, Duarte G, Foss MC, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006;22(1):59-63
100. Gonzalez-Tome MI, Ramos Amador JT, Guillen S, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 2008;9:868-74
101. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007;196:e331-3
102. Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006;107:1115-19
103. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-Analysis. AIDS 2007;21:607-1
104. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004;18:2337-9
105. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth J Infect Dis 2006;193:1195-201
106. Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008;9:6-13
107. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 2008;22:1815-20
108. Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007;195:913-14
109. Sibiude J, Warszawski J, Tubiana R, et al. ANRS CO1/CO11 Large increase in prematurity between 1990 and 2009 in HIV-infected women in the national ANRS French Perinatal Cohort: does ritonavir boost play a role [abstract 743]. 18th Conference on Retroviruses and Opportunistic Infections; Feb 27-Mar 2, 2011; Boston, MA
110. Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010;201:1035-44
111. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006;20:2345-53
112. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: A note of caution. J Infect Dis 2012;206:1639-41
113. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007;21:1019-26
114. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIVinfected women in Botswana. J Infect Dis 2012;206:1695-705
115. Parekh N, Ribaudo H, Souda S, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-Age infants among HIV-exposed and HIVunexposed infants in Botswana. Int J Gynaecol Obstet 2011;115:20-5
116. Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013;207:612-21
117. Dola CP, Khan R, DeNicola N, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2011;40:51-5
118. Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009;23:1235-43
119. Ivanovic J, Nicastri E, Anceschi MM, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res 2009;7:620-5
120. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100-2
121. Rondinini C, Venerosi A, Branchi I, et al. Long-term effects of prenatal 3'-Azido-3'-deoxythymidine (AZT) exposure on intermale aggressive behaviour of mice. Psychopharmacology (Berl) 1999;145:317-23
122. Fujinaga M, Schulte M, Holodniy M. Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Teratology 2000;62:108-14
123. Venerosi A, Valanzano A, Alleva E, Calamandrei G. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001;63:26-37
124. Calamandrei G, Valanzano A, Puopolo M, Aloe L. Developmental exposure to the antiretroviral drug zidovudine increases brain levels of brainderived neurotrophic factor in mice. Neurosci Lett 2002;333:111-14
125. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002;29:323-9
126. Bishop J B, Tani Y, Witt K, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004;81:512-17
127. Thorne C, Newell ML. Antenatal and neonatal antiretroviral therapy in HIVinfected women and their infants: A review of safety issues. Med Wieku Rozwoj 2003;7:425-36
128. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIVinfected mothers. J Acquir Immune Defic Syndr 2003;33:175-83
129. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114:598-603
130. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 2006;118:e1071-7
131. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIVinfected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000;918:212-21
132. Dominguez K, Bertolli J, Fowler M, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children
133. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000;918:222-35
134. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006;118:1139-45
135. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Jama 1999;281:151-7
136. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003;17:2053-61
137. Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007;45:43-51
138. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7
139. El Beitune P. Duarte G. Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIVexposed, uninfected newborn infant. Eur J Obstet Gynecol Reprod Biol 2006;128:59-63
140. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005;94:1571-7
141. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIVuninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006;194:1089-97
142. Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIVexposed but uninfected children. J Acquir Immune Defic Syndr 2011;57:290-6
143. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011;306:70-8
144. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol 2011;157:18-21
145. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002;29:323-9
146. Olivero OA. Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy. Mutat Res 2008;658:184-90
147. National Study of HIV in Pregnancy and Childhood (NSHPC). NSHPC update. 2012. Available from: www.nshpc.ucl.ac. uk/[[Acessed on 5th June 2014]
148. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Register International Interim Report for 1 January 1989 through 31 January 2013. 25 (1) ed Registry Coordinating Center; Wilmington, NC, USA: 2013
149. Nightingale SL. From the Food and Drug Administration. JAMA 1998;280:1472
150. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002;162:355
151. British HIV Association. Guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012;13(Suppl 2):87-157
152. Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-Analysis. AIDS 2014;28:S123-31
153. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. United states department of health and human services panel on treatment of hiv-infected pregnant women and prevention of perinatal transmission, Washington, DC; 2012. Available from: http:/aidsinfo.nih. gov/contentfiles/lvguidelines/PerinatalGL. pdf [Accessed 15 June 2013]
154. World Health Organization. Use of efavirenz during pregnancy: A public health perspective. Technical update on treatment optimization. World Health Organization, Geneva; 2012. Available from: www.who.int/hiv/pub/treatment2/efavirenz/en [Accessed 15 May 2014]
155. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009;23(3):434-5
156. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: A report of two cases. Antivir Ther 2010;15:677-80
157. Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med 2011;12:257-8
158. Weizsaecker K, Kurowski M, Hoffmeister B, et al. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS 2011;22:294-5
159. Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: A case series presentation. Int J STD AIDS 2011;22:358-60
160. Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011;16:1259-66
161. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26:1151-9
162. Martorell C, Theroux E, Bermudez A, et al. Safety and efficacy of fosamprenavir in human immunodeficiency virusinfected pregnant women. Pediatr Infect Dis J 2010;29:985
163. Cespedes MS, Castor D, Ford SL, et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr 2013;62:550-4
164. Zorrilla CD, Wright R, Osiyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med 2014;15:50-6
165. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: http://aidsinfo.nih. gov/guidelines/html/3/perinatalguidelines/0 [Accessed 5 June 2014] Last updated: March 28, 2014; last reviewed: March 28, 2014
166. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo. nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Accessed 5 June 2014]